UniProtKB/Swiss-Prot P21802 : Variant p.Ser347Cys
Fibroblast growth factor receptor 2
Feedback ?
Variant information
Variant position:
347
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
Disclaimer : Variants classification is intended for research purposes only, not for clinical and diagnostic use . The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant. ]
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
347 (S347C, p.Ser347Cys).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution).following page
Variant description:
Any additional useful information about the variant.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
347
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
821
The length of the canonical sequence.
Location on the sequence:
S IGISFHSAWLTVLPAPGREK
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human LYIRNVTFEDAGEYTCLAGNS IGISFHSAWLTVLPAPGREK
Mouse LYIRNVTFEDAGEYTCLAGNS IGISFHSAWLTVLPAPVREK
Chicken LYIRNVTFEDAGEYTCLAGNS IGISFHTAWLTVLPAPEKEK
Xenopus laevis LYVRNVSFEDAGEYTCIAGNS IGISQHSAWLTVHPAPVNPL
Zebrafish LYLPNVTFEDAGEYTCLAGNS IGISYHTAWLTVHPAETNPI
Drosophila LTLRNVTFDQEGWYTCLASSG LGRSNSSVYLRVV-SPLPPL
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
22 – 821 Fibroblast growth factor receptor 2
Topological domain
22 – 377 Extracellular
Domain
256 – 358 Ig-like C2-type 3
Glycosylation
331 – 331 N-linked (GlcNAc...) asparagine
Alternative sequence
250 – 361 Missing. In isoform 17.
Alternative sequence
255 – 821 Missing. In isoform 8.
Alternative sequence
314 – 429 Missing. In isoform 9.
Alternative sequence
341 – 353 TCLAGNSIGISFH -> ICKVSNYIGQANQ. In isoform 3, isoform 4, isoform 11, isoform 12, isoform 13 and isoform 16.
Alternative sequence
361 – 361 P -> PKQQ. In isoform 3, isoform 4, isoform 11, isoform 12, isoform 13 and isoform 16.
Literature citations
Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2.
Jabs E.W.; Li X.; Scott A.F.; Meyers G.A.; Chen W.; Eccles M.; Mao J.; Charnas L.R.; Jackson C.E.; Jaye M.;
Nat. Genet. 8:275-279(1994)
Cited for: VARIANTS CS CYS-328 AND CYS-347; VARIANT JWS GLY-344;
Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis.
Kan S.-H.; Elanko N.; Johnson D.; Cornejo-Roldan L.R.; Cook J.; Reich E.W.; Tomkins S.; Verloes A.; Twigg S.R.F.; Rannan-Eliya S.; McDonald-McGinn D.M.; Zackai E.H.; Wall S.A.; Muenke M.; Wilkie A.O.M.;
Am. J. Hum. Genet. 70:472-486(2002)
Cited for: VARIANTS CS CYS-105; PRO-267; VAL-276; CYS-281; PRO-289; ARG-338; HIS-340; PHE-342; TRP-342; CYS-347; CYS-354; HIS-549 AND GLY-678; VARIANTS PS PHE-172; 252-SER-PRO-253 DELINS PHE-SER; CYS-290; CYS-340; PRO-341; ARG-342; SER-342; CYS-375; GLY-565; ARG-641 AND GLU-663; VARIANTS APRS TRP-252 AND ARG-253; VARIANTS CS/PS PHE-278 AND TYR-342; VARIANT CRANIOSYNOSTOSIS ASN-659; VARIANTS THR-186 AND SER-315;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.
